S&P upgrades EssilorLuxottica to A+ on medtech pivot
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- S&P Global Ratings has upgraded EssilorLuxottica SA's (EPA:ESLX) long-term issuer credit rating to 'A+' from 'A', citing the company's successful pivot from a traditional consumer goods business into an integrated medtech leader. The rating agency affirmed the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe rating upgrade signals more stable growth, a positive factor for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01S&P raised the long-term rating from 'A' to 'A+' with a stable outlook.
- 02S&P projects revenue growth of 4.6% in 2026 and about 7.5% a year in 2027-2028.
- 03The medtech strategy has reduced dependence on discretionary spending cycles.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets